Canine parvovirus (CPV) is one of the most common causes of mortality in puppies worldwide. Protection against CPV infection is based on vaccination, but maternally-derived antibodies (MDA) can interfere with vaccination. The aim of this study was to evaluate the applicability of an in-clinic ELISA test to assess the CPV MDA in unvaccinated puppies and CPV antibodies in bitches, comparing the results with the gold standard haemagglutination inhibition (HI) test. Serum samples of 136 unvaccinated puppies were tested, along with sera of 16 vaccinated bitches. Five unvaccinated puppies were retested after vaccination. Both assays showed that the 16 vaccinated bitches had protective antibody levels against CPV. Conversely, significant discrepancies were observed for the MDA titers in unvaccinated puppies. Protective MDA titers were observed in 91.9% puppies using HI and in 40.4% by the in-clinic ELISA test, and only the latter one showed a decrease of MDA titers and percentages of protected puppies after the first weeks of age. Vaccination of five puppies with high HI and low in-clinic ELISA MDA titers resulted in seroconversion. Our results confirm the reliability of the in-clinic ELISA test in determining protective antibodies against CPV in adult dogs. Our findings also suggest that the in-clinic ELISA test kit may also be a useful tool to detect and quantify CPV MDA, thus allowing prediction of the best time to vaccinate puppies and reduction of the rate of vaccination failures due to interference by maternally-derived antibodies.

犬细小病毒（CPV）是全世界幼犬最常见的死亡原因之一。预防CPV感染的方法是基于疫苗接种，但是母源抗体（MDA）可能会干扰疫苗接种。这项研究的目的是评估临床ELISA试验的适用性，以评估未接种幼犬中的CPV MDA和母犬中的CPV抗体，并将结果与​​金标准血凝抑制（HI）试验进行比较。测试了136个未接种疫苗的幼犬的血清样本以及16个已接种疫苗的母犬的血清。接种疫苗后，对五只未接种疫苗的幼犬进行了重新测试。两种测定均显示16个接种的母犬具有针对CPV的保护性抗体水平。相反，在未接种疫苗的幼犬中，MDA滴度存在显着差异。在91中观察到了保护性MDA滴度。使用HI的幼犬占9％，通过临床ELISA测试的幼犬占40.4％，只有后者在成年后的头几周内显示MDA滴度和受保护幼犬的百分比降低。用高HI和低临床ELISA MDA滴度对五只幼犬进行疫苗接种可导致血清转化。我们的结果证实了临床ELISA试验在确定成年犬抗CPV的保护性抗体方面的可靠性。我们的研究结果还表明，临床ELISA测试试剂盒也可能是检测和定量CPV MDA的有用工具，从而可以预测最佳的疫苗接种时间，并减少因母源干扰而导致的疫苗接种失败率抗体。而只有后者显示出在头几周后MDA效价和受保护幼犬的百分比降低。用高HI和低临床ELISA MDA滴度对五只幼犬进行疫苗接种可导致血清转化。我们的结果证实了临床ELISA试验在确定成年犬抗CPV的保护性抗体方面的可靠性。我们的研究结果还表明，临床ELISA测试试剂盒也可能是检测和定量CPV MDA的有用工具，从而可以预测最佳的疫苗接种时间，并减少因母源干扰而导致的疫苗接种失败率抗体。而只有后者显示出在头几周后MDA效价和受保护幼犬的百分比降低。用高HI和低临床ELISA MDA滴度对五只幼犬进行疫苗接种可导致血清转化。我们的结果证实了临床ELISA试验在确定成年犬抗CPV的保护性抗体方面的可靠性。我们的研究结果还表明，临床ELISA测试试剂盒也可能是检测和定量CPV MDA的有用工具，从而可以预测最佳的疫苗接种时间，并减少因母源干扰而导致的疫苗接种失败率抗体。我们的结果证实了临床ELISA试验在确定成年犬抗CPV的保护性抗体方面的可靠性。我们的研究结果还表明，临床ELISA测试试剂盒也可能是检测和定量CPV MDA的有用工具，从而可以预测最佳的疫苗接种时间，并减少因母源干扰而导致的疫苗接种失败率抗体。我们的结果证实了临床ELISA试验在确定成年犬抗CPV的保护性抗体方面的可靠性。我们的研究结果还表明，临床ELISA测试试剂盒也可能是检测和定量CPV MDA的有用工具，从而可以预测最佳的疫苗接种时间，并减少因母源干扰而导致的疫苗接种失败率抗体。